{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable&page=34", "query": { "intervention": "Injectable", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 14388, "total_pages": 1439, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T03:03:46.999Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02355184", "title": "An Extension of Protocol PRO 140_CD01 Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "PRO 140 350mg weekly subcutaneous (SC) injection.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2014-11-18", "completion_date": "2022-07-15", "has_results": true, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02355184" }, { "nct_id": "NCT03387852", "title": "Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "SAR440340", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Fluticasone or Fluticasone/salmeterol combination", "type": "DRUG" }, { "name": "Placebo for SAR440340", "type": "DRUG" }, { "name": "Placebo for dupilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 296, "start_date": "2018-03-12", "completion_date": "2019-08-07", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387852" }, { "nct_id": "NCT00491335", "title": "HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections", "AIDS", "Lung Cancer", "Tobacco Addiction", "Drug Addiction" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": null, "start_date": "2007-06-18", "completion_date": "2010-02-16", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00491335" }, { "nct_id": "NCT03799484", "title": "Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Forehead Rhytides", "Forehead Wrinkles" ], "interventions": [ { "name": "Botulinum toxin type A", "type": "DRUG" }, { "name": "2.5% lidocaine/2.5% prilocaine", "type": "DRUG" }, { "name": "petrolatum ointment", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2019-01-04", "completion_date": "2019-06-14", "has_results": true, "last_update_posted_date": "2020-06-18", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03799484" }, { "nct_id": "NCT00633152", "title": "Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Infection" ], "interventions": [ { "name": "ceftaroline", "type": "DRUG" }, { "name": "linezolid", "type": "DRUG" }, { "name": "Aztreonam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2008-02", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 13, "location_summary": "Buena Park, California • Long Beach, California • Los Angeles, California + 10 more", "locations": [ { "city": "Buena Park", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rolling Hills Estate", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633152" }, { "nct_id": "NCT07869043", "title": "A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "tilrekimig", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 1100, "start_date": "2026-09-30", "completion_date": "2029-08-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 3, "location_summary": "Pittsburgh, Pennsylvania • Austin, Texas • Tomball, Texas", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" }, { "city": "Tomball", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869043" }, { "nct_id": "NCT03152058", "title": "IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk Pregnancy", "Pregnancy Complications", "Antiphospholipid Syndrome in Pregnancy", "Lupus Anticoagulant Disorder" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Ware Branch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 55, "start_date": "2017-05-17", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 2, "location_summary": "New York, New York • Salt Lake City, Utah", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152058" }, { "nct_id": "NCT04163458", "title": "Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infertility" ], "interventions": [ { "name": "MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL", "type": "DRUG" }, { "name": "MENOPUR powder and solvent for solution for injection, 75 IU", "type": "DRUG" }, { "name": "Placebo (for MENOPUR solution for injection in pre-filled pen)", "type": "OTHER" }, { "name": "Placebo (for MENOPUR powder and solvent for solution for injection)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "FEMALE", "summary": "18 Years to 42 Years · Female only" }, "enrollment_count": 405, "start_date": "2019-10-25", "completion_date": "2021-07-16", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 20, "location_summary": "Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04163458" }, { "nct_id": "NCT01996826", "title": "A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Corneal Neovascularization", "Corneal Graft Failure" ], "interventions": [ { "name": "Avastin® (bevacizumab)", "type": "DRUG" }, { "name": "0.9% NaCl & Refresh Liquigel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reza Dana, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2014-04", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 3, "location_summary": "Miami, Florida • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01996826" }, { "nct_id": "NCT00943943", "title": "Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Leukemia" ], "interventions": [ { "name": "G-CSF", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2010-10-29", "completion_date": "2017-03-23", "has_results": false, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-22T03:03:46.999Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943943" } ] }